Sandy Witzling
Surgery · Maywood, CANPI 1972539179
Payments from drug & device makers
Across 416 payments — averaging $29.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Bayer$1K
- Johnson & Johnson$949
- GSK$785
- Amgen$694
- Novo Nordisk$637
- plus $3K from 23 others
What the payments were for
- Food & beverage$12,069100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 112 | $4,429 |
| Bayer | 37 | $1,183 |
| Johnson & Johnson | 55 | $949 |
| GSK | 30 | $785 |
| Amgen | 28 | $694 |
| Novo Nordisk | 25 | $637 |
| Merck | 19 | $559 |
| Novartis | 20 | $450 |
| Amarin Pharma, Inc. | 10 | $430 |
| AbbVie(2 entities) | 13 | $389 |
| Lilly USA, LLC | 13 | $338 |
| Phathom Pharmaceuticals, Inc. | 5 | $214 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $204 |
| Sanofi-aventis U.S. LLC | 6 | $115 |
| Eisai Inc. | 7 | $111 |
| Sumitomo Pharma America, Inc. | 3 | $96 |
| Esperion Therapeutics, Inc. | 4 | $92 |
| Dexcom, Inc. | 4 | $77 |
| Boehringer Ingelheim | 2 | $52 |
| Insmed, Inc. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Cequr Corporation | 1 | $29 |
| Ardelyx, Inc. | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Cvrx, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,069 in reported general payments places this provider in the 75th percentile of 2,363 surgery providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 601 | $381,169 |
| KerendiaFinerenone | 264 | $194,760 |
| LinzessLinaclotide | 357 | $193,416 |
| XareltoRivaroxaban | 217 | $135,591 |
| TrulicityDulaglutide | 136 | $129,701 |
| EliquisApixaban | 127 | $86,266 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 99 | $59,350 |
| OzempicSemaglutide | 49 | $44,708 |
| JanuviaSitagliptin Phosphate | 75 | $41,065 |
| DapagliflozinDapagliflozin Propanediol | 73 | $38,729 |
| JardianceEmpagliflozin | 53 | $38,024 |
| EntrestoSacubitril/Valsartan | 51 | $35,436 |
| TradjentaLinagliptin | 67 | $35,269 |
| BrilintaTicagrelor | 79 | $35,049 |
| Advair HfaFluticasone Propion/Salmeterol | 77 | $30,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $4,429 | $475,568779 claims |
| BayerKerendia | $1,183 | $194,760264 claims |
| AbbVieLinzess | $389 | $193,416357 claims |
| Johnson & JohnsonXarelto | $949 | $135,591217 claims |
| Lilly USA, LLCTrulicity | $338 | $129,701136 claims |
| Boehringer IngelheimJardiance, Tradjenta | $52 | $73,293120 claims |
| Novo NordiskOzempic, Rybelsus | $637 | $64,47866 claims |
| MerckJanuvia | $559 | $41,06575 claims |
| NovartisEntresto | $450 | $35,43651 claims |
| GSKTrelegy Ellipta | $785 | $29,20945 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $115 | $28,66132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,363 surgery providers in California.
Other surgery in Maywood
- Timothy ChuterSan Francisco$8.9M
- Peter StockSan Francisco$6.5M
- Santiago HorganSan Diego$2.8M
- Kenneth DeckLaguna Hills$2.4M
- Daniel RiskinSan Jose$2.2M
- Michael DemeureNewport Beach$1.7M
- Rock LiuHayward$1.6M
- David LouriePasadena$1.4M
- Andrea PakulaThousand Oaks$1.4M
- Siew-Ming LeeFresno$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.